Modern Imaging Methods in the Diagnosis of Neurodegenerative Diseases
DOI:
https://doi.org/10.12775/QS.2025.38.58200Keywords
neurodegenerative disease, imaging, cortical atrophy, Alzheimer's diseaseAbstract
Neurodegenerative diseases, such as Alzheimer's, Parkinson's and other forms of dementia, represent a major global health challenge. Early diagnosis and monitoring of disease progression are key to effective management of these conditions. Advanced brain imaging techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission tomography (SPECT) and functional magnetic resonance imaging (fMRI), play a key role in the diagnosis and monitoring of neurodegenerative diseases. This article outlines the various imaging methods, their application in the context of major neurodegenerative diseases, as well as the advantages and limitations of each. In addition, the prospects for the development of these technologies, including the use of artificial intelligence and new biomarkers in diagnosis, are also discussed.
References
1. Kenneth Kaitin, Christopher Milne. The schizophrenia of corporations. "Science World." No. 9 (241), p. 18, September 2011. Prószyński Media
2. Barbara Rędzia-Ogrodnik, Tomasz Litwin, Anna Członkowska, Assessment of
"Brain cortical atrophy in neurodegenerative as well as selected neurological disorders - assessment methods and significance in diagnosis," Neuropsychiatry and Neuropsychology/Neuropsychiatry and Neuropsychology, 12 (1), 2017, pp. 20-29.
3. Walecki, J., Pawlowska-Detko, A., & Adamczyk, M. (2007). The role of modern imaging methods in the diagnosis and monitoring of dementia. Via Medica, 1734-5251. medical center for postgraduate education, CSK MSWiA in Warsaw.
4. Pavese N, Kiferle L, Piccini P. Neuroprotection and imaging studies in Parkinson's disease. Parkinsonism and related disorders. 2010
5. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease. Archives of Neurology. 1999
6. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurology. 2006
7. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Archives of Neurology. 1993
8. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in Parkinson's disease: a prospective study. Canadian Journal of Neurological Sciences. 1991
9. Damier P, Hirsch EC, Agid Y. et al. The black matter of the human brain. I. Nigrosomes and black matter matrix, compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999
10. Lehéricy S, Bardinet E, Poupon C. et al. 7 Tesla magnetic resonance imaging. A closer look at the anatomy of the black matter in Parkinson's disease. Mov Disord 2014
11. Schwarz ST, Afzal M, Morgan PS. et al. The "dovetail" appearance of the healthy nigrosome-a new accurate test of Parkinson's disease. A case-control study and retrospective cross-sectional MRI study at 3T. PLoS ONE 2014
12. Schwarz ST, Mougin O, Xing Y. et al. Signal change associated with Parkinson's disease in nigrosomes 1-5 and black matter using T2*-weighted 7T MRI. Neuroimage Clin 2018
13. Xing Y, Sapuan A, Dineen RA. et al. Changes in black matter pigmentation during life detected by neuromelanin-sensitive magnetic resonance imaging
14. Jin L, Wang J, Wang C. et al. Combined visualization of nigrosome-1 and neuromelanin in black matter using 3T MRI for differential diagnosis of spontaneous tremor and de novo Parkinson's disease. Frontline Neurol 2019
15. Trifonova OP, Maslov DL, Balashova EE. et al. Parkinson's disease. Available clinical and promising omics tests for diagnosis, disease risk assessment and personalization of pharmacotherapy. Diagnostics (Basel) 2020
16. Martin-Bastida A, Lao-Kaim NP, Loane C. et al. Motor associations of iron accumulation in gray matter nuclei in Parkinson's disease. A cross-sectional study of iron susceptibility in magnetic resonance imaging. Eur J Neurol 2017
17. Chen Q, Chen Y, Zhang Y. et al. Iron deposition in Parkinson's disease by quantitative susceptibility mapping. BMC Neurosci 2019
18. Langkammer C, Schweser F, Krebs N. et al. Quantitative susceptibility mapping (QSM) as a way to measure brain iron? A post mortem validation study. Neuroimage 2012
19. Sioka C, Fotopoulos A, Kyritsis AP. Recent advances in PET imaging in the evaluation of Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging. 2010
20. Pavese N, Kiferle L, Piccini P. Neuroprotection and imaging studies in Parkinson's disease. Parkinsonism and related disorders. 2010
21. Pavese N, Brooks DJ. Imaging neurodegeneration in Parkinson's disease. Biochimica et Biophysica Acta. 2009
22. Courbon F., Brefel-Courbon C., Thalamas C. et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov. Disord. 2003
23. Siderowf A., Stern M.B. Preclinical diagnosis of Parkinson's disease: are we there yet? Curr. Neurol. Neurosci. Rep. 2006
24. Schuff N, Wu IW, Buckley S, Foster ED, Coffey CS, Gitelman DR, et al. Diffusion-weighted imaging of black matter lesions in early dopamine-deficient Parkinson's disease. Mov Disord. (2015)
25. Prakash BD, Sitoh YY, Tan LC, Au WL. Asymmetric imaging indices of rostral black matter diffusion tensor in Parkinson's disease. Parkinsonism Relat Disord. (2012) 18:1029-33. 10.1016/j.parkreldis.2012
26. Langley J, Huddleston DE, Merritt M, Chen X, McMurray R, Silver M, et al. A reappraisal of black matter diffusion tensor imaging in Parkinson's disease. Hum Brain Mapp. (2016)
27. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006
28. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Predicting the global burden of Alzheimer's disease. Alzheimer's and Dementia. 2007
29. Kadir A, Nordberg A. Targeted PET probes for dementia-related neurodegenerative disorders. Journal of Nuclear Medicine. 2010
30. Rędzia-Ogrodnik B., Litwin T., Członkowska A. Assessment of cortical atrophy in neurodegenerative diseases and selected neurological diseases - methods of assessment and importance in diagnosis. Neuropsychiatry and Neuropsychology. 2017
31. Apostolova LG, Dutton RA, Dinov ID, et al. Conversion of Mild Cognitive Impairment to Alzheimer Disease Predicted by Hippocampal Atrophy Maps. Arch Neurol 2006
32. Wagner A.D. Early detection of Alzheimer's disease: an fMRI marker for people at risk? Nat. Neurosci. 2000
33. Bookheimer S.Y., Strojwas M.H., Cohen M.S. et al. Patterns of brain activation in people at risk for Alzheimer's disease. N. Eng. J. Med. 2000
34. Smith C.D., Andersen A.H., Kryscio R.J. et al. Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology 1999
35. Klunk W.E., Engler H., Nordberg A. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004
36. Varma A.R., Talbot P.R., Snowden J.S. et al. A 99mTc-HMPAO single-photon emission computed tomography study of Lewy body disease. J. Neurol. 1997
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Paulina Dorota Pietrukaniec , Bartosz Omasta , Katarzyna Kamińska-Omasta, Olga Krupa, Daria Rybak, Kuba Borys Romańczuk, Magdalena Agata Czerska, Szymon Przemysław Stolarczyk, Zofia Martyna Wójcik, Kinga Furtak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 282
Number of citations: 0
